Joint Advisory Committee Backs Janssen’s NDA for Treatment-Resistant Depression

Drug Industry Daily
A A
A joint FDA advisory committee voted in favor of the safety, efficacy and risk-benefit profile of Janssen’s NDA for treatment of treatment-resistant depression.

To View This Article:

Login

Subscribe To Drug Industry Daily